Form 4: CFO Maynard Acquires 400,000 Foghorn Stock Options

Foghorn Therapeutics Inc.'s Chief Financial Officer, Ryan D. Maynard, was granted 400,000 stock options with an exercise price of $5.75.

Summary

• Ryan D. Maynard, Chief Financial Officer of Foghorn Therapeutics Inc. (FHTX), acquired 400,000 stock options.
• The options have an exercise price of $5.75 per share.
• The earliest transaction date for this grant is February 23, 2026.
• The options will vest as to 25% of the underlying shares of common stock on February 23, 2027.
• Following the initial vesting, the remaining options will vest at a rate of 6.25% of the underlying shares on the first day of each calendar quarter until fully vested.
• The expiration date for these stock options is February 22, 2036.
• Following this transaction, Mr. Maynard beneficially owns 400,000 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, indicating continued executive commitment and a standard practice for incentivizing long-term performance, which aligns management's interests with shareholders.

Positives

• The grant of 400,000 stock options to the Chief Financial Officer aligns management's financial interests with long-term shareholder value creation.
• The option grant serves as an incentive for the CFO to contribute to the company's sustained growth and performance over the next decade.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's financial performance or strategic direction, beyond the vesting schedule of the granted options.

Industry Context

StockSavvy.ai notes that equity compensation, such as stock option grants, is a standard practice in the biotechnology and pharmaceutical industries. This approach is widely used to attract, retain, and incentivize key executives by linking their compensation directly to the company's stock performance and long-term success, which is crucial in a sector with long development cycles and high R&D costs.

Comparison to Industry Standards

• StockSavvy.ai observes that granting stock options to key executives like CFOs is a common compensation strategy across the biotechnology sector, similar to practices at companies such as Moderna or BioNTech, aiming to align management incentives with shareholder value creation.
• The vesting schedule, with an initial cliff vesting followed by quarterly installments over several years, is a typical structure designed to encourage long-term commitment and performance, consistent with industry benchmarks.

Stakeholder Impact

• Shareholders: The option grant aligns the CFO's financial incentives with the company's stock performance, potentially benefiting shareholders through motivated leadership.
• Employees: This transaction is specific to executive compensation and does not directly impact the broader employee base, though it reflects the company's compensation philosophy.

Next Steps

• The options will continue to vest quarterly at a rate of 6.25% of the underlying shares after the initial 25% vesting on February 23, 2027, until fully vested.

Key Dates

Recommendation

The grant of stock options to the CFO is a routine executive compensation event and does not provide new fundamental information to warrant a change in investment recommendation. It primarily serves to align executive incentives with long-term company performance, which is generally a positive but not a catalyst for immediate price movement.

Keywords

Foghorn Therapeutics, FHTX, Ryan D. Maynard, Stock Option, CFO, Insider Transaction, Equity Compensation, SEC Form 4